Table 1.
Characteristics of the study group*
| Variable | Overall (n = 150) |
Patients included in the analysis† (n = 137) |
|---|---|---|
| Age, years | ||
| Mean ± SD | 58 ± 6.4 | 58 ± 6.4 |
| Gender | ||
| Male | 145 (96.7) | 132 (96.4) |
| Female | 5 (3.3) | 5 (3.7) |
| BMI kg/m2‡ | ||
| Mean ± SD | 28 ± 4.2 | 28 ± 4.2 |
| Underweight | 0 (0.0) | 0 (0.0) |
| Normal weight | 28 (18.9) | 24 (17.8) |
| Overweight | 77 (52.0) | 69 (51.1) |
| Obese I | 35 (23.7) | 34 (25.2) |
| Obese II | 6 (4.1) | 6 (4.4) |
| Obese III | 2 (1.4) | 2 (1.5) |
| Risk factors‡ | ||
| Transfusion | 13 (26.0) | 13 (27.1) |
| IVD | 27 (40.3) | 25 (38.5) |
| ETOH | 49 (68.1) | 48 (69.5) |
| Tattoos | 17 (30.9) | 15 (28.9) |
| Body piercings | 9 (18.0) | 7 (14.9) |
| Risky sexual behavior | 17 (34.0) | 15 (32.6) |
| Medical history‡ | ||
| Diabetes mellitus | 43 (28.9) | 40 (29.4) |
| Hepatitis B | 9 (6.0) | 8 (5.9) |
| HIV | 5 (3.4) | 3 (2.2) |
| Genotype | ||
| Genotype non-1 | 34 (22.7) | 33 (24.1) |
| Genotype 1 | 116 (77.3) | 104 (75.9) |
Note: BMI = body mass index; IVD = intravenous drug; ETOH = ethyl alcohol; HIV = human immunodeficiency virus.
‡
Risks factors (Refers to receipt/consumption/presence/practice of any of the listed factors)
*
Number of participants (percent) is presented unless otherwise indicated.
*
Includes patients receiving one of the treatments (peginterferon alfa-2a + ribavirin or peginterferon alfa-2b + ribavirin).
†
Total may not equal the overall sample size because of missing values.